Pfizer's (PFE) COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Pfizer's (PFE) COVID Pill Best in Class, Will Put Pressure on Merck (MRK) and Regeneron (REGN) - Analyst
November 5, 2021 8:47 AM EDT(Updated - November 5, 2021 8:54 AM EDT)
Earlier today, Pfizer Inc. (NYSE: PFE) announced its investigational novel COVID-19 oral antiviral candidate, PAXLOVID, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR study of non-hospitalized adult patients with COVID-19,... More
Airlines, Reopening Stocks Surge Following Data From Pfizer (PFE) Antiviral Covid Pill
November 5, 2021 7:25 AM EDTAirlines, Reopening Stocks Surge Following Data From Pfizer (NYSE: PFE) Antiviral Covid Pill
American Airlines (NASDAQ: AAL) +4..8%United Airlines (NASDAQ: UAL) +3.8%Delta Air Lines (NYSE: DAL) +4.9%Southwest Airlines (NYSE: LUV) +3.9%Carnival Corp. (NYSE: CCL) +4.7%Royal Caribbean (NYSE: RCL) +4.8%Norwegian Cruise Line (NYSE: NCLH) +5.8%... More
Pfizer (PFE) Surges 8%, Merck (MRK) Down 5% Following Pfizer's COVID-19 Oral Antiviral Treatment Data
November 5, 2021 6:49 AM EDTPfizer (NYSE: PFE) Surges 8%, Merck (NYSE: MRK) Down 5% Following Pfizer's COVID-19 Oral Antiviral Treatment Data
... MoreBiden sets COVID-19 vaccine rules for businesses, prompting Republican backlash
November 4, 2021 8:50 AM EDTBy Nandita Bose, David Shepardson, Ahmed Aboulenein and Tom Hals
WASHINGTON (Reuters) -President Joe Biden will enforce a mandate that workers at U.S. companies with at least 100 employees be vaccinated against COVID-19 or be tested weekly starting Jan. 4, spurring legal challenges from Republican governors who say Biden is overstepping his authority.
Within hours governors from Florida, Iowa and Indiana had vowed to fight the new rule, arguing it infringes on individual freedom.
Despite growing political opposition, the delayed roll-out of the mandate offered a reprieve to businesses facing labor shortages during the holiday season. Biden's... More
Vaccines-at-work Mandate Rules Issued By Biden Administration - Bloomberg
November 4, 2021 8:45 AM EDTVaccines-at-work Mandate Rules Issued By Biden Administration - Bloomberg
... MorePfizer (PFE) PT Raised to $44 at Mizuho Securities
November 4, 2021 6:36 AM EDTMizuho Securities analyst Vamil Divan raised the price target on Pfizer (NYSE: PFE) to $44.00 (from $43.00) while maintaining a Neutral rating.... More
Popular stocks with increasing volume: PFE GME BB UBER AAL HOOD BBBY
November 3, 2021 3:07 PM EDTPopular stocks with increasing volume: PFE GME BB UBER AAL HOOD BBBY
... MorePfizer (PFE) PT Raised to $46 at Wolfe Research
November 3, 2021 6:04 AM EDTWolfe Research analyst Tim Anderson raised the price target on Pfizer (NYSE: PFE) to $46.00 (from $41.00) while maintaining a Peerperform rating.... More
Pfizer (PFE) PT Raised to $44 at Barclays
November 3, 2021 4:35 AM EDTBarclays analyst Carter Gould raised the price target on Pfizer (NYSE: PFE) to $44.00 (from $41.00) while maintaining a Equalweight rating.... More



